Active Ingredient(s): Imipenem + Cilastatin +Relebactam
FDA Approved: * July 16, 2019
Pharm Company: * MERCK SHARP DOHME
Category: Antibiotics

Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio,[1] is a fixed-dose combination medication used as an antibiotic. In 2019, it was approved for use in the United States for the treatment of complicated urinary tract and complicated intra-abdominal infections.[2][3][4][5] It is administered via intravenous injection.[6][1] The most common adverse reactions include... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Recarbrio Intravenous Injection, Powder, for Solution
NDC: 0006-3856
Merck Sharp & Dohme Corp.